Radiopharmaceutical developer Cerveau Technologies announced a research collaboration agreement with Ionis Pharmaceuticals for use of its F-18 MK-6240 investigational tau imaging agent for PET scans.
The radiopharmaceutical is to be used in PET scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer's disease, according to the firm. The collaboration will use MK-6240 as a biomarker in studies on neurodegenerative disease research conducted by Ionis. Cerveau and Ionis will collaborate to evaluate the effect of therapies on the progression of neurodegenerative diseases.
